Oral arguments in appeal of ‘793 PTAB decision set for December 4, 2023 PDUFA goal date to add PH-ILD indication to YUTREPIA label is January 24, 2024 Hired sales force in preparation of potential positive legal and regulatory outcomes MORRISVILLE, N.C. , Nov.

MORRISVILLE, N.C. , Oct. 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its third quarter 2023 financial results on Tuesday, November 7, 2023 . The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a

Sets PDUFA goal date of January 24, 2024 If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C. , Sept. 25, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that the U.S.

Asserts ‘793 patent in new litigation filed under Hatch-Waxman Act in response to Liquidia’s amendment to its NDA to add PH-ILD to YUTREPIA™ label Litigation is tied to same ‘793 patent previously ruled invalid by Patent Trial and Appeal Board (PTAB) MORRISVILLE, N.C. , Sept.

MORRISVILLE, N.C. , Aug. 10, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) ( Liquidia or the Company) today reported financial results for the second quarter ended June 30, 2023 . The Company will host a webcast at 8:30 a.m. ET to discuss the financial results and provide a corporate

MORRISVILLE, N.C. , Aug. 03, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its second quarter 2023 financial results on Thursday, August 10, 2023 . The company will host a webcast at 8:30 a.m. Eastern Time to discuss financial results and provide a

No new clinical data is required to add PH-ILD indication as per FDA correspondence Recertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for Tyvaso Preparing for potential launch of YUTREPIA between end of 2023 to mid-2024 MORRISVILLE, N.C.

Infringement case now only focused on ‘793 patent, previously found to be invalid by PTAB in IPR Federal Circuit expected to hear appeal of PTAB decision in late 4th quarter 2023 to early 2024 If PTAB decision affirmed, Liquidia will request final regulatory approval for YUTREPIA™ (treprostinil)

Liquidia exclusively licenses North American rights to L606, an inhaled formulation of treprostinil administered twice-daily with a short duration, next-generation nebulizer Liquidia funds $10 million upfront payment from finance agreement with HealthCare Royalty Pharmosa to receive up to $215

MORRISVILLE, N.C. , May 31, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (the Company) (NASDAQ: LQDA) announced today that Mr. Roger Jeffs , Chief Executive Officer, and Mr. Michael Kaseta , Chief Financial Officer, will provide an update on the Company's business during a fireside chat at the